# Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

> **NCT03244176** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Austin Health** · enrollment: 28 (actual)

## Conditions studied

- Lymphomas Non-Hodgkin's B-Cell

## Interventions

- **DRUG:** Avelumab

## Key facts

- **NCT ID:** NCT03244176
- **Lead sponsor:** Austin Health
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-07-21
- **Primary completion:** 2022-06-16
- **Final completion:** 2025-07
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2024-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03244176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03244176, "Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03244176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*